Protein tyrosine phosphatases as emerging targets for cancer immunotherapy
British Journal of Pharmacology, Volume 183, Issue 6, Page 1233-1249, March 2026.Abstract Contemporary strategies in cancer immunotherapy, despite remarkable success, remain constrained by inherent limitations such as suboptimal patient responses, the emergence of drug resistance, and the manifestation of pronounced adverse effects. Consequently, the need for alternative strategies for immunotherapy becomes clear.
Zihan Qu, Jiajun Dong, Zhong‐Yin Zhang
wiley +1 more source
Response to the letter regarding 'Construction and validation of a nomogram prediction model for predicting the risk of chemotherapy-induced myelosuppression after chemotherapy in patients with triple-negative breast cancer'. [PDF]
Transl Cancer ResXie H, Zhang R, Wei C, Xu J, Wang X.
europepmc +1 more source
Cancer Science, Volume 117, Issue 3, Page 769-776, March 2026.The OS for patients after achieving PFS24 or PFS60 was not markedly different from that of the age‐, sex‐, and calendar period‐matched Japanese general population (PFS24: standardized mortality ratio [SMR] 1.29, 95% confidence interval [CI] 0.72–2.12, p = 0.39; PFS60: SMR 1.43, 95% CI 0.47–3.33, p = 0.55).
Ayumi Fujimoto +11 more
wiley +1 more source
Misdiagnosis of oropouche virus in cancer patients: mimicry of treatment-related complications. [PDF]
Ann Med Surg (Lond)Jamshed S, Danaf N.
europepmc +1 more source
Infections in Chronic Lymphocytic Leukemia: Evolving Risks and Prevention Strategies
European Journal of Haematology, Volume 116, Issue 3, Page 204-214, March 2026.ABSTRACT Infections remain a leading cause of morbidity and mortality in patients with chronic lymphocytic leukemia (CLL), reflecting both intrinsic immune dysfunction and therapy‐related immunosuppression. The pathogenesis of immunodeficiency in CLL is multifactorial: neoplastic B cells impair humoral immunity, T cells are functionally exhausted, and ...
Enrica Antonia Martino +10 more
wiley +1 more source
[Retracted] Uvangoletin induces mitochondria‑mediated apoptosis in HL‑60 cells <i>in vitro</i> and <i>in vivo</i> without adverse reactions of myelosuppression, leucopenia and gastrointestinal tract disturbances. [PDF]
Oncol RepZheng Z +11 more
europepmc +1 more source
Phase 1 Dose Escalation of Single‐Agent Mechlorethamine in Dogs With Lymphoma
Veterinary and Comparative Oncology, Volume 24, Issue 1, Page 51-57, March 2026.ABSTRACT Mechlorethamine is commonly prescribed to dogs at 3 mg/m2. The minimal toxicity observed indicates that higher doses of mechlorethamine are likely tolerable. The primary objective of this study was to determine the maximally tolerated dose (MTD) of mechlorethamine in dogs with lymphoma.
Laura E. Chadsey +2 more
wiley +1 more source
Case Report: Life-threatening cisplatin-induced myelosuppression in pediatric osteosarcoma: molecular mechanisms, pharmacogenomic profiling, and targeted clinical management. [PDF]
Front PharmacolDai C, Zhang Y, Zhang Y, Dong Y.
europepmc +1 more source
Serum Symmetric Dimethylarginine as a Predictor of Toxicity of Carboplatin in Dogs
Veterinary and Comparative Oncology, Volume 24, Issue 1, Page 140-149, March 2026.ABSTRACT Glomerular filtration rate (GFR) predicts carboplatin clearance and myelotoxicity in humans and cats. This relationship is unknown in dogs. In canines, elevated serum symmetric dimethylarginine (SDMA) correlates with reduced GFR. This study prospectively evaluated whether dogs with elevated SDMA (> 14 μg/dL) are at increased risk of ...
Alexandra Gareau +3 more
wiley +1 more source
Combination of azathioprine and prednisolone as a treatment for meningoencephalomyelitis of unknown origin in dogs: 54 cases. [PDF]
J Vet Intern MedDiop S +5 more
europepmc +1 more source